Abstract
The regulatory role of prolactin (Prl) on peripheral blood natural killer (NK) and lymphokine-activated killer (LAK) cell activities was studied in young (mean age, 40 years) and elderly (mean age, 68 years) healthy men and patients with carcinoma of the oral cavity (oral cancer). The peripheral blood NK cells, but not the LAK cells, were found to be depressed in oral cancer patients compared with age-matched healthy men. However, age-associated deficiency in both NK and LAK cell activity was observed in healthy men and cancer patients. Prl produced dose-dependent inhibition (1, 10, 100 or 250 ng/ml) or stimulation (25-50 ng/ml) of resting NK cells in young groups of healthy men and cancer patients. In elderly groups less or no response of the NK cells to low doses of Prl (1-10 ng/ml) was evident. The NK cells of young and elderly healthy men were stimulated by human recombinant Interleukin-2 (rIL-2) (100 U/ml), and Prl (1-25O ng/ml) inhibited these cells. In oral cancer patients an altered response to low doses of Prl (1-5O ng/ ml) was observed in IL-2-stimulated NK cells, which also revealed malignancy- associated loss of IL-2 response. In contrast, there was no malignancy or age-associated change in Prl response of the LAK c...Continue Reading
References
Oct 29, 1979·Biochemical and Biophysical Research Communications·J DjianeP A Kelly
Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P SabharwalW B Malarkey
Jan 2, 1992·International Journal of Cancer. Journal International Du Cancer·R Biswas, U Chattopadhyay
Oct 1, 1991·Proceedings of the Society for Experimental Biology and Medicine·R R Gala
Oct 1, 1991·Immunology Today·T RoszmanW Brooks
Aug 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·C V ClevengerM B Prystowsky
Dec 1, 1990·Proceedings of the Society for Experimental Biology and Medicine·J Meites
Apr 1, 1990·The International Journal of Neuroscience·L MateraF Veglia
Dec 1, 1989·Cellular Immunology·F M OrsonD L Nelson
Oct 31, 1989·Biochemical and Biophysical Research Communications·J F Bazan
Jan 1, 1988·Cancer Immunology, Immunotherapy : CII·M EuraT Ishikawa
Oct 1, 1986·The Journal of Experimental Medicine·J R OrtaldoR Overton
Apr 1, 1988·The Journal of Clinical Investigation·J E NagelW H Adler
Apr 15, 1988·Cellular Immunology·A B WilsonR R Coombs
Jul 1, 1985·Cellular Immunology·R S Parhar, P K Lala
Jan 1, 1988·The Journal of Clinical Investigation·S MinotaJ Winfield
Apr 1, 1986·Journal of the National Cancer Institute·M R YoungM Newby
Jan 2, 1986·The New England Journal of Medicine·L SanchoA de la Hera
Dec 1, 1987·Chest·C C LinC Y Lin
Jul 1, 1985·Cellular Immunology·P K LalaR S Parhar
Sep 1, 1984·British Journal of Haematology·S TakagiY Miura
Jun 1, 1981·Immunobiology·G BátoryG G Petrányi
Oct 1, 1994·Endocrine Reviews·N D Horseman, L Y Yu-Lee
Jan 1, 1995·Immunology Today·C FranceschiA Cossarizza
May 1, 1993·Immunology Today·R HoogheE L Hooghe-Peters
Citations
Dec 3, 1999·Immunology·L MateraA Biglino
Jan 6, 2000·Molecular Pathology : MP·A J WoodP G Murray
Jan 18, 2005·International Immunopharmacology·Jian ZhangZhigang Tian
May 26, 2005·International Immunopharmacology·Rathindranath BaralUtpala Chattopadhyay
Mar 7, 2006·Cancer Immunology, Immunotherapy : CII·Anamika NathNawal K Sharma
Jan 22, 2002·International Journal of Cancer. Journal International Du Cancer·Biswanath MajumderUtpala Chattopadhyay